

Madhav V Dhodapkar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5842366/madhav-v-dhodapkar-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

3,208
citations

29
h-index

56
g-index

83
ext. papers

4,030
ext. citations

6.1
avg, IF

5.49
L-index

#	Paper	IF	Citations
75	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102257	2.2	3
74	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200088	2.2	4
73	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. <i>Blood Cancer Discovery</i> , 2021 , 2, 9-12	7	11
72	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021 , 137, 3604-3615	2.2	11
71	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021 , 96, E68-E71	7.1	3
70	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. <i>Leukemia</i> , 2021 ,	10.7	3
69	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021 , 2, 600-615	7	2
68	Reply to N. Biran et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1368-1369	2.2	
67	Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. <i>Molecular Genetics and Metabolism</i> , 2020 , 129, 286-291	3.7	15
66	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. <i>JCI Insight</i> , 2020 , 5,	9.9	13
65	Risk-associated alterations in marrow T cells in pediatric leukemia. <i>JCI Insight</i> , 2020 , 5,	9.9	5
64	Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8507-8507	2.2	18
63	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 1541-1554	12.9	35
62	Tissue-resident memory-like T cells in tumor immunity: Clinical implications. <i>Seminars in Immunology</i> , 2020 , 49, 101415	10.7	5
61	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma 2020 , 8,		13
60	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1928-1937	2.2	56
59	Game of Bones: How Myeloma Manipulates Its Microenvironment. <i>Frontiers in Oncology</i> , 2020 , 10, 625199	3.3	5

58	Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?. <i>Frontiers in Immunology</i> , 2019 , 10, 2385	8.4	3
57	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019 , 125, 2364-2382	6.4	58
56	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 537-544	2	15
55	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8001-8001	2.2	13
54	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019 , 9, 94	7	59
53	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019 , 125, 416-423	6.4	22
52	MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. <i>Blood</i> , 2018 , 131, 2500-2501	2.2	12
51	Antigen-mediated regulation in monoclonal gammopathies and myeloma. <i>JCI Insight</i> , 2018 , 3,	9.9	28
50	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018 , 132, 3241-3241	2.2	1
49	Safety and Efficacy of Evomela In Myeloma Autotransplants. <i>Blood</i> , 2018 , 132, 3446-3446	2.2	0
48	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018 , 132, 3294-3294	2.2	2
47	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018 , 132, 3302-3302	2.2	
46	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018 , 3,	9.9	90
45	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. <i>Frontiers in Immunology</i> , 2018 , 9, 2204	8.4	36
44	Elotuzumab monotherapy in patients with smoldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018 , 182, 495-503	4.5	23
43	Type II NKT Cells and Their Emerging Role in Health and Disease. <i>Journal of Immunology</i> , 2017 , 198, 1015-1021	5.3	64
42	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 296-304.e24	2.2	24
41	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017 , 77, 1510-1541	10.1	81

40	Systematic evaluation of immune regulation and modulation 2017 , 5, 21		15
39	Hematologic Malignancies: Plasma Cell Disorders. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 561-568	7.1	5
38	Natural Killer T Cells in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017 , 8, 1178	8.4	130
37	A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS8053-TPS8053	2.2	2
36	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>OncImmunology</i> , 2016 , 5, e1071008	7.2	367
35	Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. <i>New England Journal of Medicine</i> , 2016 , 374, 555-61	59.2	117
34	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. <i>JCI Insight</i> , 2016 , 1, e88955	9.9	86
33	ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3905-3916	15.9	52
32	Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. <i>Blood</i> , 2016 , 128, 2139-2139	2.2	1
31	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 7944-5	11.5	6
30	MGUS to myeloma: a mysterious gammopathy of underexplored significance. <i>Blood</i> , 2016 , 128, 2599-2606	10.2	83
29	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
28	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. <i>Nature Medicine</i> , 2016 , 22, 1351-1357	50.5	86
27	Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. <i>Journal of Immunology</i> , 2015 , 194, 950-9	5.3	269
26	Conditional overexpression of TGF β 1 promotes pulmonary inflammation, apoptosis and mortality via TGF β 2 in the developing mouse lung. <i>Respiratory Research</i> , 2015 , 16, 4	7.3	42
25	Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. <i>Blood</i> , 2015 , 125, 1256-71	2.2	89
24	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). <i>Haematologica</i> , 2015 , 100, 1214-21	6.6	34
23	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>OncImmunology</i> , 2015 , 4, e998538	7.2	101

22	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015 , 125, 4042-51	2.2	78
21	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. <i>Blood</i> , 2015 , 126, 120-120	2.2	1
20	Fluzone [®] High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. <i>Blood</i> , 2015 , 126, 3058-3058	2.2	1
19	Targeting human dendritic cells in situ to improve vaccines. <i>Immunology Letters</i> , 2014 , 162, 59-67	4.1	74
18	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
17	Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. <i>Journal of Immunology</i> , 2014 , 193, 2297-303	5.3	35
16	Trial watch: Dendritic cell-based anticancer therapy. <i>OncolImmunology</i> , 2014 , 3, e963424	7.2	54
15	Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?. <i>Cancer Prevention Research</i> , 2013 , 6, 173-6	3.2	6
14	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. <i>Blood</i> , 2013 , 122, 3174-3174	2.2	2
13	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2012 , 120, 4079-4079	2.2	1
12	Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. <i>Blood</i> , 2012 , 120, 2933-2933		
11	Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study. <i>Blood</i> , 2012 , 120, 4944-4944	2.2	
10	Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols [Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS)]. <i>Blood</i> , 2012 , 120, 198-198	2.2	
9	Vaccines targeting cancer stem cells: are they within reach?. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 397-402	2.2	13
8	Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. <i>Clinical Immunology</i> , 2011 , 140, 160-6	9	43
7	Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 413-8	7.4	10
6	Immunity to stemness genes in human cancer. <i>Current Opinion in Immunology</i> , 2010 , 22, 245-50	7.8	24
5	Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. <i>Blood</i> , 2009 , 113, 793-6	2.2	51

4	Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. <i>Frontiers in Bioscience - Landmark</i> , 2009 , 14, 796-807	2.8	27
3	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. <i>Blood</i> , 2008 , 112, 1308-16	2.2	118
2	Role of chaperones and FcγR in immunogenic death. <i>Current Opinion in Immunology</i> , 2008 , 20, 512-18	7.8	12
1	Selective blockade of the inhibitory FcγRIIB in human dendritic cells and monocytes induces a type I interferon response program. <i>Journal of Experimental Medicine</i> , 2007 , 204, 1359-69	16.6	117